# A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC

> **NCT03516071** · PHASE2 · COMPLETED · sponsor: **Zai Lab (Shanghai) Co., Ltd.** · enrollment: 90 (actual)

## Conditions studied

- Hepatocellular Carcinoma (HCC)

## Interventions

- **DRUG:** Brivanib 800 mg, QD
- **DRUG:** Brivanib 400 mg, BID

## Key facts

- **NCT ID:** NCT03516071
- **Lead sponsor:** Zai Lab (Shanghai) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-17
- **Primary completion:** 2018-11-09
- **Final completion:** 2019-07-19
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2019-09-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03516071

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03516071, "A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT03516071. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*